A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
← catalyst calendarNCT07710729 · readout in 251 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-17 | estimated | When the study began enrolling |
| Primary completion | 2027-04-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: UBT251
- Drug: Oral contraceptive
- Drug: Acetaminophen
Primary outcomes
what the primary-completion date above is the date OFAUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state
measured From pre-dose on Day 8 up to 157 days
AUC ,LN,SS: The area under the LN plasma concentration time curve during a dosing interval at steady state
measured From pre-dose on Day 8 up to 157 days
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed